What is the level of liabilities of Idorsia this year?
Idorsia has a debt balance of 1.47 B CHF this year.
Idorsia Liabilities 2024
Idorsia Liabilities
1.47 B CHF
Ticker
IDIA.SW
ISIN
CH0363463438
WKN
A2DTEB
In 2024, Idorsia's total liabilities amounted to 1.47 B CHF, a -6.16% difference from the 1.57 B CHF total liabilities in the previous year.
Idorsia Aktienanalyse
What does Idorsia do?
Idorsia Ltd is a biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for patients. The company is headquartered in Switzerland and was founded in 2017 after being spun off from Actelion Ltd. Idorsia was formed by a team of experienced scientists and developers who are known in the industry for their skills and passion for researching new therapies. The company is divided into five main business areas: cardiovascular and respiratory, CNS, immunology, pain, and oncology. Through its research and development activities, Idorsia aims to address medical needs in various areas. The company's innovative therapy approaches have already shown promise and garnered significant attention in the industry. Idorsia receives support from investors and partners. Idorsia's business model is based on an extensive portfolio of already patented and yet-to-be-patented drugs. The company strives to continually optimize and expand its developments within the industry to ultimately treat patients worldwide with its therapies. It collaborates closely with various partners from the biotechnology, pharmaceutical, and other industries to bring products to market and translate scientific knowledge into clinical practice. In the cardiovascular and respiratory field, Idorsia focuses on developing therapies for pulmonary hypertension as well as severe, acute, and chronic cardiovascular diseases. The company's goal is to reduce interventions and interventions for the treatment of these diseases through new treatment options, thus effectively and sustainably improving patients' quality of life. In neurology, Idorsia is involved in research and development of new therapies for disorders of the central nervous system. Here, the company targets the treatment of severe conditions such as epilepsy, sleep disorders, Alzheimer's, and Parkinson's. The research and development activities are carried out in close collaboration with academic research centers and clinics and have already shown success in developing new therapies. In the field of immunology, the company focuses on the development of biological therapies to support the body's immune system in fighting tumors and other severe diseases. Idorsia also focuses on the advancement of personalized medicines tailored to individual patients. In terms of pain, the company focuses on developing therapies that can effectively reduce pain without affecting the patient's perception and quality of life. Idorsia is working on the development of treatment methods that span longer periods and thus serve as an effective alternative to conventional pain therapies. One of the main products introduced by Idorsia is the drug Daridorexant. The drug is a highly selective receptor antagonist developed for the treatment of sleep disorders and other sleep-related conditions. In addition, Idorsia is working on the development of new therapies in the neurology and cardiovascular disease fields. Overall, Idorsia is dedicated to providing patients with valuable and innovative treatment options and, thereby, improving their quality of life. The company relies on scientific research and continuous improvement of its products and services to ensure long-term success in the industry. Idorsia ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Idorsia's Liabilities
Idorsia's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Idorsia's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Idorsia's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Idorsia's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Idorsia’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Idorsia stock
What were the liabilities of Idorsia compared to the previous year?
The liabilities of Idorsia have increased by -6.16% dropped compared to the previous year.
What are the consequences of high debt for investors of Idorsia?
High liabilities can pose a risk for investors of Idorsia, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Idorsia?
Low liabilities mean that Idorsia has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Idorsia affect the company?
An increase in liabilities of Idorsia can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Idorsia affect the company?
A decrease in the liabilities of Idorsia can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Idorsia?
Some factors that can influence the liabilities of Idorsia include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Idorsia so important for investors?
The liabilities of Idorsia are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Idorsia take to modify the liabilities?
To change its liabilities, Idorsia can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Idorsia pay?
Over the past 12 months, Idorsia paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Idorsia is expected to pay a dividend of 0 CHF.
What is the dividend yield of Idorsia?
The current dividend yield of Idorsia is .
When does Idorsia pay dividends?
Idorsia pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Idorsia?
Idorsia paid dividends every year for the past 0 years.
What is the dividend of Idorsia?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Idorsia located?
Idorsia is assigned to the 'Health' sector.
Wann musste ich die Aktien von Idorsia kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Idorsia from 9/26/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.
When did Idorsia pay the last dividend?
The last dividend was paid out on 9/26/2024.
What was the dividend of Idorsia in the year 2023?
In the year 2023, Idorsia distributed 0 CHF as dividends.
In which currency does Idorsia pay out the dividend?
The dividends of Idorsia are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Idorsia
Our stock analysis for Idorsia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Idorsia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
